StockData
Vistagen Therapeutics, Inc. logo

Vistagen Therapeutics, Inc. (VTGN) stock

VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3078% below fair value
$0.19+0.00 (+2.01%)

Close on Nov 17, 2026Market cap $8.34MP/E –Yield –

Vistagen Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Vistagen Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$62.30M. For fiscal 2026 it was -$66.44M. The highest annual figure on record is -$841.30K in fiscal 2011.

Annual operating cash flow

PeriodPeriod endValueChange
FY2026Mar 31, 2026-$66.44M–
FY2025Mar 31, 2025-$42.10M–
FY2024Mar 31, 2024-$25.81M–
FY2023Mar 31, 2023-$49.72M–
FY2022Mar 31, 2022-$45.26M–
FY2021Mar 31, 2021-$12.07M–
FY2020Mar 31, 2020-$15.76M–
FY2019Mar 31, 2019-$14.53M–
FY2018Mar 31, 2018-$9.06M–
FY2017Mar 31, 2017-$7.26M–
FY2016Mar 31, 2016-$4.81M–
FY2015Mar 31, 2015-$2.77M–
FY2014Mar 31, 2014-$2.13M–
FY2013Mar 31, 2013-$3.46M–
FY2012Mar 31, 2012-$3.57M–
FY2011Mar 31, 2011-$841.30K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026-$14.71M–
Q4 FY2026CQ1 2026Mar 31, 2026-$16.20M–
Q3 FY2026CQ4 2025Dec 31, 2025-$17.63M–
Q2 FY2026CQ3 2025Sep 30, 2025-$13.76M–
Q1 FY2026CQ2 2025Jun 30, 2025-$18.85M–
Q4 FY2025CQ1 2025Mar 31, 2025-$10.06M–
Q3 FY2025CQ4 2024Dec 31, 2024-$10.28M–
Q2 FY2025CQ3 2024Sep 30, 2024-$10.89M–
Q1 FY2025CQ2 2024Jun 30, 2024-$10.87M–
Q4 FY2024CQ1 2024Mar 31, 2024-$6.99M–
Q3 FY2024CQ4 2023Dec 31, 2023-$4.75M–
Q2 FY2024CQ3 2023Sep 30, 2023-$6.19M–
Q1 FY2024CQ2 2023Jun 30, 2023-$7.89M–
Q4 FY2023CQ1 2023Mar 31, 2023-$7.47M–
Q3 FY2023CQ4 2022Dec 31, 2022-$9.93M–
Q2 FY2023CQ3 2022Sep 30, 2022-$16.34M–
Q1 FY2023CQ2 2022Jun 30, 2022-$15.97M–
Q4 FY2022CQ1 2022Mar 31, 2022-$15.59M–
Q3 FY2022CQ4 2021Dec 31, 2021-$12.05M–
Q2 FY2022CQ3 2021Sep 30, 2021-$11.45M-1240.7%
Q1 FY2022CQ2 2021Jun 30, 2021-$6.17M–
Q4 FY2021CQ1 2021Mar 31, 2021-$5.28M–
Q3 FY2021CQ4 2020Dec 31, 2020-$4.99M–
Q2 FY2021CQ3 2020Sep 30, 2020$1.00M–
Q1 FY2021CQ2 2020Jun 30, 2020-$2.81M–
Q4 FY2020CQ1 2020Mar 31, 2020-$2.58M–
Q3 FY2020CQ4 2019Dec 31, 2019-$4.28M–
Q2 FY2020CQ3 2019Sep 30, 2019-$4.14M–
Q1 FY2020CQ2 2019Jun 30, 2019-$4.76M–
Q4 FY2019CQ1 2019Mar 31, 2019-$3.56M–
Q3 FY2019CQ4 2018Dec 31, 2018-$3.91M–
Q2 FY2019CQ3 2018Sep 30, 2018-$3.93M–
Q1 FY2019CQ2 2018Jun 30, 2018-$3.14M–
Q4 FY2018CQ1 2018Mar 31, 2018-$2.60M–
Q3 FY2018CQ4 2017Dec 31, 2017-$2.44M–
Q2 FY2018CQ3 2017Sep 30, 2017-$1.88M–
Q1 FY2018CQ2 2017Jun 30, 2017-$2.13M–
Q4 FY2017CQ1 2017Mar 31, 2017-$1.29M–
Q3 FY2017CQ4 2016Dec 31, 2016-$2.10M–
Q2 FY2017CQ3 2016Sep 30, 2016-$2.20M–

More Vistagen Therapeutics figures

See a number that looks wrong?